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Abstract
BACKGROUND: The Pediatric Heart Network designed a clinical trial to compare
aortic root growth and other short-term cardiovascular outcomes in children and
young adults with Marfan syndrome randomized to receive atenolol or losartan.
We report here the characteristics of the screened population and enrolled
subjects. METHODS AND RESULTS: Between 2007 and 2011, 21 clinical sites
randomized 608 subjects, aged 6 months to 25 years who met the original Ghent
criteria and had a body surface area-adjusted aortic root diameter z-score >3.0.
The mean age at study entry was 11.2 years, 60% were male, and 25% were
older teenagers and young adults. The median aortic root diameter z-score was
4.0. Aortic root diameter z-score did not vary with age. Mitral valve prolapse and
mitral regurgitation were more common in females. Among those with a positive
family history, 56% had a family member with aortic surgery, and 32% had a
family member with a history of aortic dissection. CONCLUSIONS: Baselin...
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Abstract
Background—The Pediatric Heart Network designed a clinical trial to compare aortic root
growth and other short-term cardiovascular outcomes in children and young adults with Marfan
syndrome randomized to receive atenolol or losartan. We report here the characteristics of the
screened population and enrolled subjects.
Methods and results—Between 2007 and 2011, 21 clinical sites randomized 608 subjects,
aged 6 months to 25 years who met the original Ghent criteria and had a body surface area–
adjusted aortic root diameter z-score >3.0. The mean age at study entry was 11.2 years, 60% were
male, and 25% were older teenagers and young adults. The median aortic root diameter z-score
was 4.0. Aortic root diameter z-score did not vary with age. Mitral valve prolapse and mitral
regurgitation were more common in females. Among those with a positive family history, 56%
had a family member with aortic surgery, and 32% had a family member with a history of aortic
dissection.
Conclusions—Baseline demographic, clinical, and anthropometric characteristics of the
randomized cohort are representative of patients in this population with moderate to severe aortic
root dilation. The high percentage of young subjects with relatives who have had aortic dissection
or surgery illustrates the need for more definitive therapy; we expect that the results of the study
and the wealth of systematic data collected will make an important contribution to the
management of individuals with Marfan syndrome.
Marfan syndrome (MFS) is a systemic disorder of connective tissue caused by mutations in
FBN1, the gene encoding fibrillin-1.1 Cardiovascular disease, mainly aortic root dilation and
aortic dissection, is the leading cause of mortality in MFS. Although early diagnosis and
refined medical and surgical management have improved median cumulative probability of
survival from approximately 40 to 70 years, individuals with MFS continue to have high
morbidity and early mortality.2
Transforming growth factor β (TGF-β) recently emerged as a potential mediator in the
pathogenesis of MFS.3 The current hypothesis is that a deficiency of extracellular fibrillin-1
causes failure of matrix sequestration of the TGF-β large latent complex with consequent
excessive TGF-β activation and signaling, resulting in the pleiotropic MFS manifestations
including developmental emphysema, myxomatous valve disease, skeletal muscle
myopathy, and aortic root aneurysm.3-6 Studies in an Fbn1-targeted mouse model of MFS
with aortic disease similar to that seen in humans showed that treatment with losartan, an
angiotensin II receptor blocker, normalized aortic root growth and aortic wall architecture
and that these improvements correlated with reduced TGF-β activity.5
The National Heart, Lung, and Blood Institute (NHLBI)–funded Pediatric Heart Network
designed a clinical trial to compare aortic root growth and other short-term cardiovascular
outcomes in children and young adults with MFS randomized to receive losartan or atenolol,
a β-blocker, which is the current standard of therapy at most centers.7 The primary aim of
this trial is to compare the effect of atenolol therapy with that of losartan therapy on the rate
of aortic root growth over 3 years. We report here the characteristics of the screened
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population and enrolled subjects. A detailed description of the echocardiographic methods
and echocardiographic characteristics of the enrolled subjects is being reported separately.8
Methods
Screening and randomization protocol
The design of this trial has been reported.7 In brief, individuals 6 months to 25 years of age
who met the original Ghent criteria9 and had a body surface area–adjusted aortic root
diameter z-score >3.0 were eligible for inclusion (Table I). The study was designed to
include subjects with this degree of aortic dilation at the time of enrollment because these
individuals may be more likely than those with less aortic root dilation to show a treatment
effect within the 3-year time frame of this study. Similarly, we excluded subjects with
severe aortic dilation (≥5 cm) because they would likely withdraw before 3 years because of
the need for surgery. To evaluate the effect of growth on change in z-score, we compared
younger children who were still growing to older teenagers and young adults who were
expected to have achieved final height at the time of study entry (≥16 years for males and
≥15 years for females).10 The study protocol was approved by the institutional review board
or institutional ethics board at each participating center, and informed consent was obtained
from the patient or a parent or legal guardian before trial enrollment.
The study design included a multitiered screening, consent, and randomization process
summarized in Figure 1. Revised diagnostic criteria for MFS were published after initiation
of this trial.11 After completion of trial enrollment, we retrospectively compared the original
and revised Ghent diagnostic criteria in the enrolled subjects and screened population.
Nearly all the randomized subjects (603 of 608) and nonrandomized patients eligible for
consent (42/43), all of whom had an aortic root diameter z-score >3.0, satisfied both the
original and revised criteria.
Echocardiograms were performed under a standardized protocol and interpreted centrally by
investigators blinded to treatment arm. Aortic root diameter was measured at the sinuses of
Valsalva at its maximum dimension in systole, from inner edge to inner edge, in the
parasternal long-axis view,12 and body surface area–adjusted aortic root diameter z-score
was calculated.13
Statistical methods
Weight, height, and body mass index (BMI) z-scores were derived from 2000 CDC Growth
Charts.14 Descriptive statistics are shown as means ± SDs and number of subjects
(percentage); medians and interquartile ranges (IQRs) are presented for highly skewed
measures. Continuous variables were compared with analysis of variance or its
nonparametric analogue (Kruskal-Wallis) between groups. Categorical variables were
compared between groups with a Fisher exact test; ordinal variables were compared with a
Fisher exact test and the Mantel-Haenszel test for trend. Because of the large number of
comparisons, 2-sided P values < .01 were considered to be statistically significant.
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Results
Screening and randomization
Subjects were enrolled from January 2007 to February 2011 (Figure 1). The extremely high
consent rate (97%) did not allow a robust comparison of randomized subjects to fully
eligible patients who were not randomized solely because of lack of consent. However, a
comparison of randomized subjects (n = 608) to all nonrandomized patients (n = 43) who
met Ghent criteria showed no significant differences in baseline characteristics (data not
shown).
Baseline characteristics of the randomized cohort
The mean age at randomization was 11.2 years, 60% of subjects were male, and 25% of
subjects were older teenagers and young adults who were expected to have achieved their
final height at the time of randomization (Table II).10 Most of the subjects were <18 years of
age (85%).
By design of the trial, all subjects had aortic root dilation and, therefore, met the major
Ghent criterion for the cardiovascular system. The median aortic root diameter z-score was
4.0 (IQR 3.4-4.9) (Table II).
The most prevalent major criterion after the cardiovascular system was family or genetic
history (76%, Figure 2), although FBN1 status was unknown in 56% of subjects (Table II).
A family history of MFS (as defined by Ghent criteria) was reported in 62% of subjects,
with 35% of those subjects reporting 1 relative, 44% reporting 2 relatives, and 21%
reporting ≥3 relatives with MFS (Table II). Roughly a third of subjects with a family history
of MFS also reported a family history of aortic dissection, and over half of subjects with a
family history of MFS also reported a family history of aortic surgery.
Approximately half of the subjects met the major Ghent criteria for the skeletal or ocular
systems (Figure 2). Fortysix percent of subjects met 2 major Ghent criteria, and 42% met 3
major criteria (Table II). Imaging for dural ectasia varied widely by site (0%-49%); among
those with imaging (n = 95), the prevalence of dural ectasia was 34%.
Most subjects (57%) reported prior usage of β-blockers at any time before the trial, whereas
relatively few reported prior use of other antihypertensive medications. Only 3% of subjects
reported prior use of angiotensin receptor blockers.
Neurodevelopmental conditions, mainly learning disabilities, attention deficit disorder,
and/or hyperactivity, were reported in 19%. Psychiatric disorders, mainly depression and
anxiety, were reported in 6%.
As expected, the subjects, in general, were thin and tall, as indicated by their weight, height,
and BMI z-scores (Table III). Specifically, BMI was 1 SD below normal, and height was, on
average, 2 SDs above normal. The median arm span–to–height ratio was normal (1.03), and
the median upper-to-lower segment ratio was 0.89. Most subjects (60%) had an abnormally
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reduced upper-to-lower segment ratio; young children (≤6 years) were much more likely to
have a reduced ratio (online Appendix B Supplemental Table I).
Baseline demographic, clinical, and anthropometric characteristics (Table II and Table III)
did not differ by assigned treatment arm (P > .2) with the exception of reported endocrine
disorders (P = .007); the number of subjects reporting an endocrine disorder was small (n =
7).
Gender differences
Among those with a family history of MFS, a family history of aortic surgery was more
common in females than males (71% vs 47%, P < .001) (Figure 3). The prevalence of mitral
valve prolapse (MVP) and measurable (mild or more) mitral regurgitation (MR) was higher
among female subjects (MVP: females 45% vs males 33%, P = .006, MR: females 25% vs
males 13%, P < .001). A history of neurodevelopmental disorders requiring therapy was
more common in males than in females (24% vs 12%, P < .001). These associations with
gender were not modified by age at randomization (gender by age interaction P > .1).
Excluding anthropometric measurements, other characteristics, including aortic root
diameter z-score, did not differ between females and males (online Appendix B
Supplemental Table II).
Age effects
Aortic root diameter z-score was not dependent on age (online Appendix B Supplemental
Table I). Prior administration of β-blockers was more common in older subjects (P < .001).
As expected, older subjects were also more likely to report a positive history of
cardiovascular and psychiatric disorders (P ≤ .006). Although older subjects met a higher
number of major Ghent criteria and were more likely to meet major criteria in the skeletal
system and dura specifically, the prevalence of was not dependent on age (Figure 4). Older
subjects were also more likely to show involvement of the pulmonary system and skin.
Aortic root diameter z-score
We examined the associations of quartiles of aortic root diameter z-score at randomization
with other baseline characteristics (online Appendix B Supplemental Table III). Subjects
with higher aortic root diameter z-scores were more likely to have other cardiovascular
involvement (MVP and/or dilated main pulmonary artery, P = .006). In contrast, subjects
with aortic root diameter z-scores in the first quartile (aortic root diameter z-score ≤3.42)
were more likely to have a family history of MFS than subjects with larger aortic root
diameter z-scores (75% vs 57%, P < .001). Aortic root diameter z-score was negatively
correlated with weight-for-age z-score (P < .001) and BMI (both raw and BMI-for-age z-
score, P < .001). No other significant associations were identified.
Family history
Data on family history were available for all but 24 subjects. Among subjects with available
data, 62% (n = 360) had a positive family history of MFS, a characteristic that showed no
association with age at randomization (positive family history 11.0 ± 6.8 years of age, no
family history 11.6 ± 5.7 years of age, P = .3). Of note, among those with a positive family
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history, 56% had a family member with aortic surgery, and 32% had a family member with
a history of aortic dissection (Table II). Those with a positive family history also had
slightly lower median aortic root diameter z-scores (3.9 vs 4.2, P < .001) and were less
likely to meet major criteria in the skeletal system (41% vs 59%, P < .001). No other
significant associations were identified.
FBN1 mutation status
The frequency of FBN1 testing varied widely by site (range 19%-96%), and FBN1 mutation
status was unknown (FBN1 testing not done) in 56% of the randomized subjects, precluding
robust analysis. FBN1 mutation status was associated with age at randomization (presence of
FBN1 mutation 9.3 ± 5.6 years, absence of FBN1 mutation 12.8 ± 6.5 years, and FBN1
mutation status unknown 12.0 ± 6.4 years, P < .001). Among those with FBN1 testing, (n =
268), 71% had a defined FBN1 mutation, and 29% did not.
Ectopia lentis was more likely in subjects with unknown FBN1 status (55% vs 39% in
subjects with a documented mutation and 42% in subjects without a mutation, age-adjusted
P = .001). Subjects with a documented mutation were less likely than those without a
mutation to have a family history of MFS (46% vs 64%, age-adjusted P = .002). No other
significant associations were identified.
Discussion
We have successfully enrolled a very large cohort of pediatric and young adult patients with
MFS from 21 international sites into this trial comparing cardiovascular outcomes in
subjects randomized to receive atenolol or losartan. This cohort is different from most
previously published large series of MFS patients15-17 because of the range of age (6
months-25 years) and aortic root diameter z-score requirement for enrollment. The high
percentage of subjects <18 years of age in this large cohort is novel.
With a few exceptions, the prevalence rates of the major and minor Ghent criteria were
similar in our cohort compared with previously published series. By study design, all
subjects had aortic root dilation and, therefore, met major Ghent criteria for the
cardiovascular system. Older studies reported a higher prevalence of ectopia lentis of 60% to
70%, probably as result of selection bias; the prevalence of ectopia lentis in our series (48%)
was similar to recently published large series (47%-54%).15-17 Imaging for dural ectasia was
available in only 95 subjects (16%), and the prevalence was lower in our cohort compared
with previous reports (34% vs 63%-92%).1 The prevalence of striae was similar (44% vs
47%),16 but pulmonary involvement was lower compared with published reports (3% vs
4%-15%).1
Older subjects in this trial were more likely to exhibit more major and minor manifestations
than younger subjects, but the prevalence of ectopia lentis was not dependent on age,
consistent with the concept that ectopia lentis is most commonly detected at a young age in
MFS.18 Similarly, aortic root diameter z-score did not vary with age in our cohort of
children and young adults selected for moderate to severe aortic dilation. Although a
selection bias cannot be completely excluded, the absence of variation in aortic root
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diameter z-score with age in our cross-sectional sample is consistent with previous
longitudinal studies that have shown that aortic root diameter z-score is stable (z-score
change per year close to 0), at least in young individuals with MFS.19 It is important to
emphasize that, in growing individuals, the aortic root continues to enlarge despite a stable
z-score. Subjects with higher aortic root diameter z-scores were more likely to have
additional cardiovascular involvement—MVP and/or dilation of the main pulmonary artery.
That 60% of our cohort is male is intriguing, given that MFS is an autosomal dominant
disorder and a balanced gender ratio is expected. The male predominance was present
throughout the screening process including the initial medical record review, suggesting that
the gender ratio reflected the general Marfan population, but the reason for this is unclear.
Several studies in children and adults have also shown a male predominance
(54%-60%).15-17,20
Mitral valve prolapse and measurable (mild or more) MR were more common in females in
our cohort. In contrast, Detaint et al20 found no gender differences in MVP or MR among
965 probands with pathogenic FBN1 mutations, but their cohort had a median age at
diagnosis of 22 years, leaving open the possibility of an increased risk for MVP/MR in
younger females. Of note, Detaint et al also found that men presented earlier and with more
severe aortic dilation and related complications compared with the women. Similar trends of
earlier and more severe aortic disease are observed in male Fbn1-deficient mice (personal
communication, Harry C. Dietz, MD, 2012). However, aortic root diameter z-score was not
dependent on gender in our randomized cohort. Thus, more severe disease in males cannot
completely account for the greater proportion of males in the overall MFS population.
Hofman et al21 evaluated the neurodevelopmental status and cognitive ability of 30
consecutive school-aged children with MFS (70% male) and found ≥1 neuropsychologic
deficits—learning disability, attention deficit disorder with or without hyperactivity,
neuromaturational immaturity, and verbal performance discrepancy—in half of them (33%
of the girls and 62% of the boys). Neurodevelopmental issues were more common in males
in our cohort, but our estimates of prevalence were based on medical history and not on the
results of formal testing. Whether the male predilection is specific for MFS or reflective of
general population trends is unclear; further investigation with formal neuropsychologic
testing and long-term follow-up is warranted.
Limitations
The study design only included individuals with at least moderate aortic root dilation and
excluded patients at the extremes of the spectrum of aortic disease in MFS. Patients with
aortic root diameter z-scores ≤3 and those with previous or impending aortic surgery were
excluded. Although the randomized subjects were well characterized, the screening process
did not include detailed data collection on all screened patients as this was beyond the scope
of the study. Therefore, a robust comparison between the randomized subjects and the
screened population was not feasible.
In summary, we have characterized the largest cohort of pediatric and young adult patients
with MFS. We found that aortic root z-score did not vary with age and was not dependent on
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gender. Among those with a family history of MFS, a family history of aortic surgery was
more common in females.
The very high consent rate among eligible subjects is notable. The clinical profile of the
cohort is representative of patients in this population with moderate to severe aortic root
dilation. As expected with randomization, baseline demographic, clinical, and
anthropometric characteristics of the study cohort are not different between treatment
groups. As such, our multicenter trial is in an excellent position to evaluate the efficacy and
safety of atenolol and losartan in young patients with MFS and to determine if the benefit of
losartan in the mouse model of MFS translates to humans. The high percentage of young
subjects with relatives who have had aortic dissection or surgery illustrates the need for
more definitive therapy. We expect that the results of the study and the wealth of systematic
data collected will make an important contribution to the management of individuals with
MFS.
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Figure 1.
Flowchart of Pediatric Heart Network Marfan trial screened population. Abbreviations:
LDS, Loeys-Dietz syndrome; SGS, Shprintzen-Goldberg syndrome. a, The most common
exclusion criterion at this stage of the screening process (not mutually exclusive) was having
an aortic root diameter z-score ≤3 (71%), followed by indication of a prior aortic surgery or
dissection or aortic surgery planned within 6 months (10%) and intolerance to angiotensin
receptor blocker, angiotensin-converting enzyme inhibitor, or β-blocker (10%). A relatively
small proportion of ineligible patients indicated therapeutic usage of angiotensin-converting
enzyme inhibitor, β-blocker, or calcium-channel blockers (6%), inability to complete study
procedures (6%), current or planned pregnancy (3%), aortic root dimension >5 cm (2%), and
diabetes or renal dysfunction (1%). b, Twenty patients were ineligible following consent to
participate in the trial because of ineligible baseline echocardiogram, 24-hour ambulatory
electrocardiogram (Holter), or laboratory studies.
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Figure 2.
Prevalence of Ghent criteria in aggregate and by treatment arm. The prevalence of Ghent
criteria, both major and involvement of organ systems, is shown. Prevalence of organ
system involvement is calculated in subjects who do not meet major criteria in the respective
organ system, with the exception of cardiovascular involvement. Because all subjects had
aortic root dilation and, therefore, met the major criterion for the cardiovascular system,
cardiovascular involvement indicates the prevalence of additional minor cardiovascular
criteria of MVP and dilated main pulmonary artery in all randomized subjects.
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Figure 3.
Gender differences. Gender differences in family history of aortic surgery,
neurodevelopmental history, measurable (mild or more) mitral valve regurgitation, and
MVP. Family history of aortic surgery was restricted to subjects who indicated a family
history of MFS. **P < .01, ***P < .001.
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Figure 4.
Differences by age at randomization. Prevalence of major Ghent criteria in the skeletal,
dura, and ocular organ systems; number of major Ghent criteria met; and involvement of
pulmonary and skin organ systems by age at randomization quartiles. **P < .01, ***P < .
001.
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Table I
Trial inclusion and exclusion criteria
Inclusion criteria
1 Diagnosis of MFS by original Ghent criteria
2 Age 6 m to 25 y
3 Aortic root diameter z-score >3.0
4 Informed consent/assent of parent/legal guardian and subject
Exclusion criteria
1 Prior aortic surgery
2 Aortic root dimension ≥5 cm
3 Planned aortic surgery within 6 m of enrollment
4 Aortic dissection
5 Shprintzen-Goldberg syndrome or Loeys-Dietz syndrome
6 Therapeutic rather than prophylactic use of angiotensin-converting enzyme inhibitor, β-blocker, or calcium-channel blocker
7 History of angioedema while taking an angiotensin-converting enzyme inhibitor or β-blocker
8 Intolerance to angiotensin receptor blocker
9 Intolerance to β-blocker
10 Renal dysfunction
11 Asthma
12 Diabetes mellitus
13 Pregnancy or planned pregnancy
14 Inability to complete study procedures including history of poor acoustic windows
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Table II
Baseline demographic and clinical characteristics of randomized subjects
Baseline characteristic Randomized subjects (n = 608) Treatment A (n = 303) Treatment B (n = 305)
Age at randomization, y 11.2 ± 6.3 11.5 ± 6.5 11.0 ± 6.2
Male ≥16 y/female ≥15 y 151 (25%) 76 (25%) 75 (25%)
Male 366 (60%) 180 (59%) 186 (61%)
Race
 Asian 16 (3%) 6 (2%) 10 (3%)
 Black or African American 46 (8%) 21 (7%) 25 (8%)
 Other 20 (3%) 10 (3%) 10 (3%)
 White 526 (87%) 266 (88%) 260 (85%)
 Hispanic or Latino 82 (14%) 36 (12%) 46 (15%)
No. of major Ghent criteria met
 2 282 (46%) 137 (45%) 145 (48%)
 3 253 (42%) 125 (41%) 128 (42%)
 4 69 (11%) 39 (13%) 30 (10%)
 5 (maximum) 4 (1%) 2 (1%) 2 (1%)
Presence of causal FBN1 mutation
 Yes 189 (31%) 97 (32%) 92 (30%)
 No 79 (13%) 41 (14%) 38 (12%)
 Unknown 340 (56%) 165 (54%) 175 (57%)
Core echocardiogram laboratory reading
 Maximum aortic root diameter, cm 3.4 ± 0.7 3.4 ± 0.7 3.4 ± 0.7
 Maximum aortic root diameter z-score 4.0 (3.4, 4.9) 4.0 (3.5, 4.8) 4.0 (3.4, 5.0)
 Maximum aortic root diameter z-score ≥4.5 221 (36%) 108 (36%) 113 (37%)
Family history
 Family history of Marfan 360 (62%) 180 (61%) 180 (62%)
No. of biological relatives with Marfan
 1 126 (35%) 58 (32%) 68 (38%)
 2 157 (44%) 78 (43%) 79 (44%)
 3+ 77 (21%) 44 (24%) 33 (18%)
 Relative(s) with aortic dissection* 107 (32%) 54 (32%) 53 (32%)
 Relative(s) with aortic surgery* 196 (56%) 101 (57%) 95 (56%)
Medical history
 Cardiac surgery 12 (2%) 6 (2%) 6 (2%)
 Cardiovascular 75 (12%) 39 (13%) 36 (12%)
 Endocrine 7 (1%) 7 (2%) 0 (0%)
 Neurodevelopmental 117 (19%) 56 (19%) 61 (20%)
 Psychiatric 39 (6%) 23 (8%) 16 (5%)
Medications history
 β-Blocker 343 (57%) 173 (57%) 170 (56%)
 Angiotensin-converting enzyme inhibitor 34 (6%) 12 (4%) 22 (7%)
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Baseline characteristic Randomized subjects (n = 608) Treatment A (n = 303) Treatment B (n = 305)
 Calcium-channel blocker 8 (1%) 4 (1%) 4 (1%)
 Angiotensin receptor blocker 18 (3%) 10 (3%) 8 (3%)
 Other antihypertensive 2 (0.3%) 0 (0%) 2 (1%)
 Any antihypertensive 361 (59%) 178 (59%) 183 (60%)
 Prerandomization washout required 241 (40%) 114 (38%) 127 (42%)
Data are shown as mean ± SD, median (interquartile range), or n (%). Baseline demographic and clinical characteristics are not statistically
different between treatment arms (P > .2) with the exception of positive endocrine history (P = .007).
*
In subjects who reported a family history of MFS.
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Table III
Baseline anthropometric characteristics
Baseline characteristic Randomized subjects (n = 608) Treatment A (n = 303) Treatment B (n = 305)
Weight, kg 36.0 (22.4, 58.7) 38.1 (23.0, 57.5) 34.6 (21.8, 58.8)
Weight-for-age z-score (≤20 y)* 0.3 ± 1.1 0.2 ± 1.2 0.3 ± 1.1
Weight-for-height z-score (<120.5 cm)† −1.1 ±1.6 −1.1 ± 1.6 −1.0 ± 1.6
Height, cm 155 (126, 178) 160 (127, 178) 152 (125, 178)
Height-for-age z-score (≤20 y)* 2.0 ± 1.2 1.9 ± 1.1 2.0 ± 1.2
BMI, kg/m2 16.7 ± 3.6 16.8 ± 3.7 16.6 ± 3.6
BMI-for-age z-score (≤20 y)* −1.2 ± 1.6 −1.2 ± 1.7 −1.2 ± 1.6
Arm span, cm 162 (128, 185) 165 (130, 185) 158 (128, 184)
Arm span–to–height ratio 1.03 (1.00, 1.05) 1.03 (1.01, 1.05) 1.03 (1.00, 1.05)
US/LS ratio 0.89 (0.81, 0.98) 0.88 (0.81, 0.97) 0.89 (0.81, 0.98)
Reduced US/LS ratio‡ 360 (60%) 179 (60%) 181 (60%)
Data are shown as mean ± SD, median (interquartile range), or n (%). All baseline anthropometric characteristics are not statistically different
between treatment arms (P> .15).
Abbreviation: US/LS, Upper-to-lower segment.
*Weight-for-age z-score, height-for-age z-score, and BMI-for-age z-score are not available for individuals >20 years of age.
†Weight-for-height z-score is not available for individuals ≥120.5 cm.
‡
Reduced upper-to-lower segment ratio defined as <1.5 for 0 to 1 year, <1.4 for 1 to 2 years, <1.3 for 2 to 3 years, <1.2 for 3 to 4 years, <1.1 for 4
to 5 years, <1.0 for 5 to 6 years, <0.95 for 6 to 7 years, <0.90 for 7 to 8 years, and <0.85 for >8 years.
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